JP2008506714A - オーロラキナーゼインヒビターとして有用なチエノピリミジン - Google Patents

オーロラキナーゼインヒビターとして有用なチエノピリミジン Download PDF

Info

Publication number
JP2008506714A
JP2008506714A JP2007521708A JP2007521708A JP2008506714A JP 2008506714 A JP2008506714 A JP 2008506714A JP 2007521708 A JP2007521708 A JP 2007521708A JP 2007521708 A JP2007521708 A JP 2007521708A JP 2008506714 A JP2008506714 A JP 2008506714A
Authority
JP
Japan
Prior art keywords
alkyl
aryl
heteroaryl
compound
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007521708A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008506714A5 (https=
Inventor
ウィラード ルー，
サブラマニアン バスカラン，
ジョアン ディー． オスロブ，
ジョシュ ヨバーン，
ミン チョン，
Original Assignee
サネシス ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サネシス ファーマシューティカルズ， インコーポレイテッド filed Critical サネシス ファーマシューティカルズ， インコーポレイテッド
Publication of JP2008506714A publication Critical patent/JP2008506714A/ja
Publication of JP2008506714A5 publication Critical patent/JP2008506714A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2007521708A 2004-07-16 2005-07-15 オーロラキナーゼインヒビターとして有用なチエノピリミジン Pending JP2008506714A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58871804P 2004-07-16 2004-07-16
US63256804P 2004-12-01 2004-12-01
PCT/US2005/025340 WO2006036266A1 (en) 2004-07-16 2005-07-15 Thienopyrimidines useful as aurora kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2008506714A true JP2008506714A (ja) 2008-03-06
JP2008506714A5 JP2008506714A5 (https=) 2008-08-14

Family

ID=35527256

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007521708A Pending JP2008506714A (ja) 2004-07-16 2005-07-15 オーロラキナーゼインヒビターとして有用なチエノピリミジン

Country Status (14)

Country Link
US (2) US7601725B2 (https=)
EP (1) EP1768984B1 (https=)
JP (1) JP2008506714A (https=)
KR (1) KR20070057792A (https=)
AT (1) ATE485300T1 (https=)
AU (1) AU2005290226A1 (https=)
BR (1) BRPI0513405A (https=)
CA (1) CA2573999A1 (https=)
DE (1) DE602005024274D1 (https=)
IL (1) IL180722A0 (https=)
MX (1) MX2007000631A (https=)
NZ (1) NZ552751A (https=)
SG (1) SG156650A1 (https=)
WO (1) WO2006036266A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009113637A1 (ja) * 2008-03-12 2009-09-17 東ソー株式会社 新規なチアゾール誘導体、チアゾール誘導体固定化マトリックス、及びそれらの製造方法
JP2009244252A (ja) * 2008-03-13 2009-10-22 Sagami Chem Res Center 新規なチアゾール誘導体固定化マトリックス、及びその製造方法
JP2010159239A (ja) * 2008-03-12 2010-07-22 Sagami Chemical Research Institute 新規なチアゾール誘導体、及びその製造方法
JP2016501192A (ja) * 2012-11-20 2016-01-18 ケイテーベー ツモルフォルシュングスゲゼルシャフト ミット ベシュレンクテル ハフツング プロテインキナーゼ阻害剤としてのチオエーテル誘導体
WO2016199761A1 (ja) * 2015-06-08 2016-12-15 石原産業株式会社 ジフルオロメチレン化合物

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2438017T3 (es) 2004-07-30 2014-01-15 Methylgene Inc. Inhibidores de la señalización del receptor del VEGF y del receptor del HGF
AU2006313456B2 (en) 2005-05-20 2011-06-23 Methylgene Inc. Inhibitors of VEGF receptor and HGF receptor signaling
KR101378716B1 (ko) 2005-05-20 2014-04-10 메틸진 인코포레이티드 Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달의 억제제
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
CN101405001A (zh) * 2006-03-20 2009-04-08 霍夫曼-拉罗奇有限公司 抑制btk和syk蛋白质激酶的方法
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
US7968536B2 (en) * 2007-06-29 2011-06-28 Millennium Pharmaceuticals, Inc. Heterocyclic compounds useful as RAF kinase inhibitors
EP2014663A1 (de) * 2007-07-12 2009-01-14 Bayer Schering Pharma AG Thienopyrimidylamine als Modulatoren des EP2-Rezeptors
NZ588355A (en) 2008-03-05 2012-03-30 Methylgene Inc Inhibitors of protein tyrosine kinase activity
US20110293745A1 (en) * 2008-03-14 2011-12-01 Sunesis Pharmaceuticals, Inc. Aurora kinase inhibitors
WO2009120795A1 (en) * 2008-03-25 2009-10-01 Sunesis Pharmaceuticals, Inc. Methods of chemotype evolution
CN102014627B (zh) * 2008-04-30 2014-10-29 国家卫生研究院 作为极光激酶抑制剂的稠合双环嘧啶化合物
CN102186479A (zh) * 2008-09-10 2011-09-14 凯利普西斯公司 用于治疗疾病的组胺受体的氨基嘧啶抑制剂
US9006252B2 (en) * 2008-09-26 2015-04-14 National Health Research Institutes Fused multicyclic compounds as protein kinase inhibitors
RU2535032C2 (ru) 2008-12-22 2014-12-10 Милленниум Фармасьютикалз, Инк. Сочетание ингибиторов аврора киназы и анти-cd 20 антител
CN103012428A (zh) 2013-01-08 2013-04-03 中国药科大学 4-(五元杂环并嘧啶/吡啶取代)氨基-1H-3-吡唑甲酰胺类CDK/Aurora双重抑制剂及其用途
EP3076963A4 (en) 2013-12-06 2017-09-13 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2017015316A1 (en) 2015-07-21 2017-01-26 Millennium Pharmaceuticals, Inc. Administration of aurora kinase inhibitor and chemotherapeutic agents
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
US20220305048A1 (en) 2019-08-26 2022-09-29 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61286373A (ja) * 1985-06-14 1986-12-16 Sankyo Co Ltd フエノキシアルキルアミン誘導体、その製法および殺虫殺ダニ剤
WO1997009316A1 (en) * 1995-09-04 1997-03-13 Novartis Ag 4-[2-(pyrimidin-4-oxy- or 4-ylamino)-ethyl]-phenyl-oximes
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
WO2002051849A1 (en) * 2000-12-26 2002-07-04 Daiichi Pharmaceutical Co., Ltd. Cdk4 inhibitors
US6503914B1 (en) * 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
WO2003055890A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1570494A (en) 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
US4196207A (en) 1977-05-23 1980-04-01 Ici Australia Limited Process for controlling eradicating or preventing infestations of animals by Ixodid ticks
JPH0720943B2 (ja) 1988-08-19 1995-03-08 宇部興産株式会社 アミノピリミジン誘導体、その製法及び殺虫・殺菌剤
US5141941A (en) 1988-11-21 1992-08-25 Ube Industries, Ltd. Aralkylamine derivatives, and fungicides containing the same
JPH075569B2 (ja) 1989-08-02 1995-01-25 宇部興産株式会社 アラルキルアミン誘導体、その製法及び殺菌、殺虫剤
US5124333A (en) 1989-08-02 1992-06-23 Ube Industries, Ltd. Aminopyrimidine derivatives and harmful organisms preventive agent
JPH0717638B2 (ja) 1989-08-02 1995-03-01 宇部興産株式会社 アミノピリミジン誘導体、その製造方法及び殺虫、殺菌剤
JPH03173872A (ja) 1989-09-14 1991-07-29 Ube Ind Ltd アミノピリミジン誘導体、その製造方法及び殺虫・殺菌剤
EP0424125A3 (en) 1989-10-18 1991-10-09 Ube Industries, Ltd. Aralkylamine derivatives, preparation method thereof and fungicides containing the same
DE4008726A1 (de) 1990-03-19 1991-09-26 Basf Ag Thieno(2,3-d)pyrimidinderivate
AU651337B2 (en) 1990-03-30 1994-07-21 Dowelanco Thienopyrimidine derivatives
JPH04164072A (ja) 1990-10-26 1992-06-09 Ube Ind Ltd オキシピリミジン誘導体、その製法及び有害生物防除剤
JP2762430B2 (ja) 1991-01-18 1998-06-04 宇部興産株式会社 アラルキルアミノピリミジン類の製法
US5227387A (en) 1991-09-03 1993-07-13 Dowelanco Quinoline nematicidal method
DE4131924A1 (de) 1991-09-25 1993-07-08 Hoechst Ag Substituierte 4-alkoxypyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel
US5187168A (en) 1991-10-24 1993-02-16 American Home Products Corporation Substituted quinazolines as angiotensin II antagonists
JPH0710712A (ja) 1993-06-25 1995-01-13 Ube Ind Ltd 花卉園芸用殺菌剤
US5654307A (en) 1994-01-25 1997-08-05 Warner-Lambert Company Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
GB9424676D0 (en) 1994-12-07 1995-02-01 Sandoz Ltd Organic compounds
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
DE69717453T2 (de) 1996-06-06 2003-07-10 Otsuka Pharmaceutical Factory, Inc. Amid derivate
DE19827611A1 (de) 1997-07-25 1999-01-28 Basf Ag Verwendung von Arylalkylaminoderivaten als Insektizide
JP3937367B2 (ja) 1998-02-05 2007-06-27 株式会社大塚製薬工場 一酸化窒素合成酵素阻害剤
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
US6407124B1 (en) 1998-06-18 2002-06-18 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
EP1087951B9 (en) 1998-06-18 2006-09-13 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
US6414156B2 (en) 1998-10-21 2002-07-02 Bristol-Myers Squibb Company Process for preparing azacycloalkanoylaminothiazoles
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
EP1161431A4 (en) 1999-03-10 2002-04-24 Merck & Co Inc 6-AZAINDOL COMPOUNDS AS AN ANTAGONISTS OF THE GONADOTROPIN RELEASE HORMONES
AU3514200A (en) 1999-03-10 2000-09-28 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
EP1169038B9 (en) 1999-04-15 2013-07-10 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
GB2350111A (en) 1999-05-17 2000-11-22 Bayer Ag Oligohydroxyl substituted 3-urea-benzofuran and pyridofuran derivatives
GB2350112A (en) 1999-05-17 2000-11-22 Bayer Ag Pharmaceutically active cycloalkyl ketones
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
SV2002000205A (es) 1999-11-01 2002-06-07 Lilly Co Eli Compuestos farmaceuticos ref. x-01095
US6515004B1 (en) 1999-12-15 2003-02-04 Bristol-Myers Squibb Company N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
JP2004501863A (ja) 2000-01-19 2004-01-22 アルテオン　インコーポレーテッド チアゾール、イミダゾールおよびオキサゾール化合物、ならびにタンパク質老化関連疾患の治療
KR100774855B1 (ko) 2000-04-27 2007-11-08 아스텔라스세이야쿠 가부시키가이샤 축합 헤테로아릴 유도체
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
US6534531B2 (en) 2000-04-27 2003-03-18 Bristol-Myers Squibb Company Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy
JP2002105081A (ja) 2000-07-28 2002-04-10 Nikken Chem Co Ltd 新規チオフェンニ環化合物
US6627767B2 (en) 2000-08-29 2003-09-30 Abbott Laboratories Amino(oxo) acetic acid protein tyrosine phosphatase inhibitors
WO2002018321A2 (en) 2000-08-29 2002-03-07 Abbott Laboratories Amino(oxo)acetic acid protein tyrosine phosphatase inhibitors
IT1318696B1 (it) 2000-09-15 2003-08-27 Pharmacia & Upjohn Spa Coniugati di glutatione con derivati della distamicina ad attivita'antitumorale.
WO2002050071A1 (en) 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases
EP1359910A4 (en) 2000-12-29 2006-07-05 Alteon Inc PROCESS FOR THE TREATMENT OF GLAUCOM II B
AU2002241670B2 (en) 2000-12-29 2006-08-17 Alteon, Inc. Method for treating glaucoma IB
WO2002053161A1 (en) 2000-12-29 2002-07-11 Alteon, Inc. Method for treating fibrotic diseases or other indications
US6693125B2 (en) 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
KR100637564B1 (ko) 2001-01-26 2006-10-20 추가이 세이야쿠 가부시키가이샤 대사 조절자로서 유용한 말로닐-코에이 데카르복실라제억제제
US6660737B2 (en) 2001-05-04 2003-12-09 The Procter & Gamble Company Medicinal uses of hydrazones
US20040235867A1 (en) * 2001-07-24 2004-11-25 Bilodeau Mark T. Tyrosine kinase inhibitors
DK1463497T3 (da) 2001-12-06 2012-01-30 Gtx Inc Behandling af muskelsvind med selektive androgenreceptormodulatorer
AU2002357193A1 (en) 2001-12-19 2003-07-09 Smithkline Beecham Corporation Thienopyrimidine compounds as protein tyrosine kinase inhibitors
WO2003055491A1 (en) * 2001-12-24 2003-07-10 Astrazeneca Ab Substituted quinazoline derivatives as inhibitors of aurora kinases
WO2003064428A1 (en) 2002-01-29 2003-08-07 H. Lundbeck A/S Furano- and thienopyrimidines as neurokinase inhibitors
CA2475108A1 (en) 2002-02-07 2003-08-14 Mitchell S. Steiner Treating benign prostate hyperplasia with sarms
WO2003090869A1 (en) 2002-04-23 2003-11-06 Chugai Seiyaku Kabushiki Kaisha Lxr modulators
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
AU2003251904A1 (en) 2002-07-15 2004-02-02 Combinatorx, Incorporated Combinations of drugs for the treatment of neoplasms
AR044743A1 (es) 2002-09-26 2005-10-05 Nihon Nohyaku Co Ltd Herbicida, metodo de emplearlo, derivados de tienopirimidina sustituida,compuestos intermediarios, y procedimientos que se utilizan para producirlos,
WO2004034978A2 (en) 2002-10-15 2004-04-29 Gtx, Inc. Treating obesity with selective androgen receptor modulators
US20040197928A1 (en) 2002-10-15 2004-10-07 Dalton James T. Method for detecting selective androgen receptor modulators
WO2004035739A2 (en) 2002-10-16 2004-04-29 Gtx, Inc. Treating androgen decline in aging male (adam)-associated conditions with sarms
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US20040171075A1 (en) 2002-12-31 2004-09-02 Flynn Daniel L Modulation of protein functionalities
WO2004110350A2 (en) 2003-05-14 2004-12-23 Torreypines Therapeutics, Inc. Compouds and uses thereof in modulating amyloid beta

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61286373A (ja) * 1985-06-14 1986-12-16 Sankyo Co Ltd フエノキシアルキルアミン誘導体、その製法および殺虫殺ダニ剤
WO1997009316A1 (en) * 1995-09-04 1997-03-13 Novartis Ag 4-[2-(pyrimidin-4-oxy- or 4-ylamino)-ethyl]-phenyl-oximes
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6503914B1 (en) * 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
WO2002051849A1 (en) * 2000-12-26 2002-07-04 Daiichi Pharmaceutical Co., Ltd. Cdk4 inhibitors
WO2003055890A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009113637A1 (ja) * 2008-03-12 2009-09-17 東ソー株式会社 新規なチアゾール誘導体、チアゾール誘導体固定化マトリックス、及びそれらの製造方法
JP2010159239A (ja) * 2008-03-12 2010-07-22 Sagami Chemical Research Institute 新規なチアゾール誘導体、及びその製造方法
JP2009244252A (ja) * 2008-03-13 2009-10-22 Sagami Chem Res Center 新規なチアゾール誘導体固定化マトリックス、及びその製造方法
JP2016501192A (ja) * 2012-11-20 2016-01-18 ケイテーベー ツモルフォルシュングスゲゼルシャフト ミット ベシュレンクテル ハフツング プロテインキナーゼ阻害剤としてのチオエーテル誘導体
WO2016199761A1 (ja) * 2015-06-08 2016-12-15 石原産業株式会社 ジフルオロメチレン化合物

Also Published As

Publication number Publication date
DE602005024274D1 (de) 2010-12-02
IL180722A0 (en) 2007-06-03
US7601725B2 (en) 2009-10-13
AU2005290226A1 (en) 2006-04-06
EP1768984A1 (en) 2007-04-04
WO2006036266A1 (en) 2006-04-06
EP1768984B1 (en) 2010-10-20
MX2007000631A (es) 2007-03-30
NZ552751A (en) 2010-11-26
ATE485300T1 (de) 2010-11-15
SG156650A1 (en) 2009-11-26
US20100179123A1 (en) 2010-07-15
CA2573999A1 (en) 2006-04-06
US20060035908A1 (en) 2006-02-16
KR20070057792A (ko) 2007-06-07
BRPI0513405A (pt) 2008-05-06

Similar Documents

Publication Publication Date Title
US7601725B2 (en) Thienopyrimidines useful as Aurora kinase inhibitors
US11987584B2 (en) Heterobicyclic amides as inhibitors of CD38
AU2005316668B2 (en) Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors
US7932257B2 (en) Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors
AU2008210266B2 (en) Thiopyrimidine-based compounds and uses thereof
US8513284B2 (en) Fused pyridine and pyrazine derivatives as kinase inhibitors
US20100130473A1 (en) Compounds
EP1463730B1 (en) Pyrazolopyridazine derivatives
US20060074056A1 (en) Inhibitors of VEGF receptor and HGF receptor signaling
MXPA06015223A (es) Furanopirimidinas.
ZA200706673B (en) Hydrazinomethyl, hydr zonomethyl and 5-membered heterocylic compounds which act as m TOR inhibitors and their use as anti cancer agents
KR20150060839A (ko) 브루톤 티로신 키나아제의 억제제
US20240279224A1 (en) Quinolines and azaquinolines as inhibitors of cd38
CN114502163A (zh) 作为rho相关卷曲螺旋激酶(rock)抑制剂的乙炔基杂环
WO2017190637A1 (zh) 用于抑制蛋白酪氨酸激酶活性的稠合嘧啶类化合物
KR20180073681A (ko) 1,4-디카르보닐-피페리딜 유도체
CN101160316A (zh) 适合用作aurora激酶抑制剂的噻吩并嘧啶
HK1116793A (en) Thienopyrimidines useful as aurora kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080625

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110516

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110518

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110815

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110818

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110822

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110825

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111116

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120208